


FFW



PATENT  
Customer No. 22,852  
Attorney Docket No. 2356.0086

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Pierre DRUILHE et al.	)	Group Art Unit: 1645
	)	
Application No.: 10/712,533	)	Examiner: Not assigned
	)	
Filed: November 14, 2003	)	
	)	Confirmation No.: 5870
For: PLASMODIUM FALCIPARUM	)	
ANTIGENS AND THEIR	)	
VACCINE AND DIAGNOSTIC	)	
APPLICATIONS	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REQUEST FOR CORRECTED FILING RECEIPT**


We are forwarding herewith a copy of a Filing Receipt for the above-identified patent application. The error appears in the residence information for the second applicant. Anne-Charlotte GRUNER's residence should read **--Montrouge, France--** and is shown in ink on the attached copy.


It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 14, 2004

By:   
Kenneth J. Meyers  
Reg. No. 25,146  
Phone: (202) 408-4033  
Fax: (202) 408-4400



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/712,533	11/14/2003	1645	1974	02356.0086	28	41	6

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
1300 I Street, N.W.  
Washington, DC 20005-3315

CONFIRMATION NO. 5870

UPDATED FILING RECEIPT



\*OC000000014642441\*

Date Mailed: 12/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Pierre Druilhe, Paris, FRANCE;

Anne-Charlotte Gruner, Paris, FRANCE;

Montrouge, France

**Power of Attorney:** The patent practitioners associated with Customer Number 22852.

**Domestic Priority data as claimed by applicant**

This application is a CON of PCT/FR02/01637 05/15/2002

**Foreign Applications**

CANADA 2,345,206 05/16/2001

CANADA 2,346,968 05/23/2001

**If Required, Foreign Filing License Granted:** 06/04/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/712,533**

**Projected Publication Date:** 03/10/2005

**Non-Publication Request:** No

**Early Publication Request:** No

12/13/04

**Title**

Plasmodium falciparum antigens and their vaccine and diagnostic applications

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).